Last Updated : October 30, 2024
Details
FilesGeneric Name:
bevacizumab and lomustine
Project Status:
Complete
Therapeutic Area:
Recurrent glioblastoma multiform
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0318-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with glioblastoma.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 06, 2023 |
|---|---|
| Call for patient/clinician input closed | May 02, 2023 |
| Clarification: - No patient input submission received | |
| Call for industry input open | March 06, 2023 |
| Call for industry input closed | May 02, 2023 |
| Submission received | March 02, 2023 |
| Review initiated | March 06, 2023 |
| Expert committee meeting (initial) | October 17, 2023 |
| Draft recommendation posted for stakeholder feedback | November 09, 2023 |
| End of feedback period | November 24, 2023 |
| Final recommendation posted | December 20, 2023 |
| Canada's Drug Agency review report(s) posted | October 30, 2023 |
Files
Last Updated : October 30, 2024